Publications by authors named "S Gessi"

Alzheimer's disease (AD) is a neurodegenerative pathology covering about 70% of all cases of dementia. It is associated with neuroinflammation and neuronal cell death, which are involved in disease progression. There is a lack of effective therapies, and halting this process represents a therapeutic challenge.

View Article and Find Full Text PDF

This commentary offers a detailed examination of a newly published paper on the effects of small molecule decoys of amyloid-β (Aβ) aggregation on microglial activation. It was discovered that the NSC16224 decoy peptide inhibited proinflammatory cytokines TNFα and IL6 release from microglia in response to Aβ and Aβ treatment. The research addresses the potential of blocking a sequence of events that lead to the progression of Alzheimer's disease (AD).

View Article and Find Full Text PDF

Microalgae are considered promising sustainable sources of natural bioactive compounds to be used in biotechnological sectors. In recent years, attention is increasingly given to the search of microalgae-derived compounds with antioxidant and anti-inflammatory properties for nutraceutical or pharmacological issues. In this context, attention is usually focused on the composition and bioactivity of algae or their extracts, while less interest is driven to their biological features, for example, those related to morphology and cultivation conditions.

View Article and Find Full Text PDF
Article Synopsis
  • The blood-brain barrier (BBB) protects the central nervous system (CNS) by controlling what substances pass from the bloodstream to the brain, balancing necessary functions while blocking harmful elements.
  • The presence of adenosine, a naturally occurring nucleoside, regulates various bodily functions via its receptors, which are seen as promising targets for drug development against CNS disorders.
  • Research indicates that adenosine can influence BBB permeability through its receptors, especially when both A1 and A2A receptors are activated simultaneously, showing potential for therapeutic applications in CNS diseases.
View Article and Find Full Text PDF

Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues of the body makes them, on the one hand, excellent candidates for numerous diseases, and on the other hand, intrinsically challenging to exploit selectively and in a site-specific manner. This review endeavors to comprehensively depict the substantial advancements witnessed in recent years concerning the development of drugs that modulate ARs.

View Article and Find Full Text PDF